Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients

Patient Preference and Adherence

Volumn 1, Issue , 2007, Pages 19-27

  Czekalla, Jörg ^a   Wagner, Thomas ^b   Schacht, Alexander ^b   Kluge, Michael ^c   Kinon, Bruce ^d  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Acute treatment; Observational study; Olanzapine; Schizophrenia

Indexed keywords

EID: 49449106319     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S2300     Document Type: Article

References (29)

1. Alvarez E., Bobes J, Gomez J-C, et al. 2003. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol, 13:39-48.
2. Baker R. W, Kinon BJ, Maguire GA, et al. 2003. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol, 23:342-8.
3. Beasley C. M, Sayler ME, Kiesler GM. 1998. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophr Res, 29:28.
4. Behnke, K, Sogaard J, Martin S, et al. 2003. Mirtazapine orally disintegrating tablet versus sertaline: a prospective onset of action study. J Clin Psychopharmacol, 23:358-64.
5. Bergstrom R. F, Mitchell M, Witcher J, et al. 2004. Rapid onset of absorption with olanzapine orally disintegrating tablets. Schizophr Res 67:160.
6. Bobes J., Gibert J, Ciudad A, et al. 2003. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 27:473-81.
7. Breier A., Meehan K, Birkett M, et al. 2002. A double-blind, placebocontrolled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59:441-8.
8. Brunner E., Domhof S, Langer F. 2002. Nonparametric analysis of longitudinal data in factorial experiments. Wiley Series in Probability and Statistics. New York: Wiley.
9. Brunner E., Munzel U. 2002. Nichtparametrische Datenanalyse. Berlin: Springer.
10. Cain E.D. 2006. Clinical perspectives on atypical antipsychotics for treatment of agitation. J Clin Psychiatry 67 (Suppl 10):22-31.
11. Chue P., Jones B, Taylor CC, Dickson R. 2002. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry, 47:771-4.
12. Cooper D., Moisan J, Grégoire JP. 2007. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 68:818-25.
13. Dowson A. J, MacGregor EA, Purdy RA, et al. 2002. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 22:101-6.
14. Glazer W.M. 1998. Formulary decision and health economics. J Clin Psychiatry 59(Suppl):23-9.
15. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology (revised). Bethesda, DM: US Department of Health, Education and Welfare.
16. Johnson D., Rai S, Milne S. 2002. Olanzapine oro-dispersible (VelotabTM)-an alternative to depot? Int J Psychiatry Clin Pract 6:163-5.
17. Kinon B. J, Hill AL, Liu H, Kollack-Walker S. 2003. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 6:97-102.
18. Kinon B. J, Volavka J, Stauffer V, et al. 2006. Standard and higher doses of olanzapine in acutely ill patients with schizophrenia or schizoaffective disorder with suboptimal prior response: a randomized double-blind fixed dose study. [Abstract]. Int J Neuropsychopharmacol 9 (Suppl 1):S281.
19. Krakowski M. I, Czobor P, Citrome L, et al. 2006. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, 63:622-9.
20. Marder S.R. 2006. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry, 67 (Suppl 10):13-21
21. Meltzer H. Y, Alphs L, Green AI, et al. 2003. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry, 60:82-91.
22. Meltzer H. Y, Okayli G. 1995. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry, 152:183-90.
23. Montgomery S. A, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry, 134:382-9.
24. Pascual J. C, Pérez V, Martín JL, Safont G, Puigdemont D, Alvarez E. 2007. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas Esp Psiquiatr, 35:47-51.
25. Soskis D.A. 1978. Schizophrenic and medical inpatients as informed drug consumers. Arch Gen Psychiatry, 35:645-7.
26. Tollefson G. D, Birkett MA, Kiesler GM, Wood AJ. Lilly Resistant Schizophrenia Study Group. 2001. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry, 49:52-63.
27. Torrey E.F. 1995. Surviving schizophrenia: A manual for families, consumers, and providers. New York: Harper Collins. p 409.
28. Volavka J., Czobor P, Sheitman B, et al. 2002. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry, 159:255-62.
29. Wright P., Birkett M, David SR, et al. 2001. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158:1149-51.